Contact
searchSearch
HMP Global
Login

March 2016

Editor's Page
What's in a Pathway?
03/08/2016
Winston Wong, PharmD
Whether or not a clinical pathways program will be effective is determined by the quality of the process used to develop the pathways. Which treatments go in the pathway; which stages of the care process are...
Whether or not a clinical pathways program will be effective is determined by the quality of the process used to develop the pathways. Which treatments go in the pathway; which stages of the care process are...
...
03/08/2016
Journal of Clinical Pathways
Perspectives
Impact of Government Cost Controls on Treatment Selection for Clinical Pathways
03/08/2016
Scott Guerin, PhD; Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
Abstract: The increasing emphasis on value-based care has led to the rise of clinical pathways and their use in various health care settings for a number of different disease states. To improve these pathways and...
Abstract: The increasing emphasis on value-based care has led to the rise of clinical pathways and their use in various health care settings for a number of different disease states. To improve these pathways and...
...
03/08/2016
Journal of Clinical Pathways
Research Reports
Effect of Route of Bortezomib Administration on Treatment Outcomes in Previously Untreated Patients with Multiple Myeloma: A Retrospective Analysis from US Community Oncology Practices
03/08/2016
Liviu Niculescu, MD; Robyn Harrell, MS; Lina Asmar, PhD; Yanyan Zhu, PhD, MPH; Esprit Ma, MPH; Vijayveer Bonthapally, PhD; Robert M. Rifkin, MD, FACP
Abstract: A phase 3 study (MMY-3021) in relapsed/refractory multiple myeloma (MM) demonstrated non-inferior efficacy and an improved systemic safety profile with subcutaneous (SC) versus intravenous (IV)...
Abstract: A phase 3 study (MMY-3021) in relapsed/refractory multiple myeloma (MM) demonstrated non-inferior efficacy and an improved systemic safety profile with subcutaneous (SC) versus intravenous (IV)...
...
03/08/2016
Journal of Clinical Pathways
Counterpoint
ASCO Policy Statement on Clinical Pathways in Oncology Represents Great Progress for Clinical Pathways
03/08/2016
Winston Wong, PharmD
The ASCO Policy Statement on Oncology Clinical Pathways shows how far clinical pathways have come in gaining acceptance among providers and supports their potential for improving the value of cancer care. The...
The ASCO Policy Statement on Oncology Clinical Pathways shows how far clinical pathways have come in gaining acceptance among providers and supports their potential for improving the value of cancer care. The...
The...
03/08/2016
Journal of Clinical Pathways
Viewpoint
Greater Alignment Among Oncology Clinical Pathways is Needed
03/08/2016
Edward Stepanski, PhD
A single, consensus-driven approach to oncology clinical pathways shared across payers appears to be a logical step if these approaches are to be indeed evidence-based and if administrative burden is to be managed...
A single, consensus-driven approach to oncology clinical pathways shared across payers appears to be a logical step if these approaches are to be indeed evidence-based and if administrative burden is to be managed...
A...
03/08/2016
Journal of Clinical Pathways
Clinical Pathways GPS
Calling it Quits: Addressing Treatment Discontinuation on a Clinical Pathway
03/08/2016
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD; Donald Ohloma, MS
Discontinuation of treatment should be considered whenever treatment benefits are exceeded by their burden. When and how patients should be discontinued from treatment, however, may not necessarily be addressed by...
Discontinuation of treatment should be considered whenever treatment benefits are exceeded by their burden. When and how patients should be discontinued from treatment, however, may not necessarily be addressed by...
...
03/08/2016
Journal of Clinical Pathways
Interview
Immunotherapies and the Future of Cancer Care
03/08/2016
Five years ago, at the American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7, 2011; Chicago, IL), investigators presented data on the immunotherapy drug ipilimumab, the first treatment to improve...
Five years ago, at the American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7, 2011; Chicago, IL), investigators presented data on the immunotherapy drug ipilimumab, the first treatment to improve...
Five...
03/08/2016
Journal of Clinical Pathways
Interview
The ASCO Perspective on Oncology Clinical Pathways
03/08/2016
In the face of rising health care costs, oncology clinical pathways have been well documented as an effective tool for reducing inefficiency and improving quality in cancer care. A 2014 study reviewing 642 patients...
In the face of rising health care costs, oncology clinical pathways have been well documented as an effective tool for reducing inefficiency and improving quality in cancer care. A 2014 study reviewing 642 patients...
In the...
03/08/2016
Journal of Clinical Pathways
Conference Coverage
2016 American Society of Clinical Oncology Quality Care Symposium
03/08/2016
A number of recent initiatives have required health care providers to think more proactively about the value of the care they deliver. This is especially true in the treatment of patients with cancer, where costs...
A number of recent initiatives have required health care providers to think more proactively about the value of the care they deliver. This is especially true in the treatment of patients with cancer, where costs...
A...
03/08/2016
Journal of Clinical Pathways
Research in Review
Stereotactic Body Radiation More Cost-Effective for Treating Prostate Cancer Than Standard Therapy
03/08/2016
Stereotactic body radiotherapy (SBRT) with a robotic system is currently more cost-effective than standard regimens as well as SBRT delivered with other systems for the treatment of prostate cancer, according to a...
Stereotactic body radiotherapy (SBRT) with a robotic system is currently more cost-effective than standard regimens as well as SBRT delivered with other systems for the treatment of prostate cancer, according to a...
...
03/08/2016
Journal of Clinical Pathways
JCP July-Aug Cover 2025

Current Issue

August 2025
Volume 11
Issue 4
Current Issue
Issue Archive

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

April 2016 Volume 2

View Issue Archive
Editorial Correspondence

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use